Department of Thoracic Surgery, Osaka City University Hospital, Osaka, Japan.
Department of Diagnostic Pathology, Osaka City University Hospital, Osaka, Japan.
Thorac Cancer. 2019 Apr;10(4):832-838. doi: 10.1111/1759-7714.13008. Epub 2019 Feb 28.
Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known cell adhesion protein.
In total, 245 patients with pathological stage I lung adenocarcinoma who underwent lobectomy with radical mediastinal lymph node dissection were identified from 1998 to 2012. Recurrence-free survival (RFS) was compared between patients stratified by STAS and the immunohistochemical intensity of SLX in the main tumor. Patients were divided into three groups based on the intensity of SLX staining: high (n = 108), moderate (n = 48), and low (n = 89).
STAS was observed in 71 patients (29.0%). Patients with STAS had significantly poorer five-year RFS (67.1%) than those without STAS (84.8%). Although no relationship was observed between the existence of STAS and SLX intensity, the distance between STAS cells and the main tumor was significantly shorter in the moderate group (median 0.9 mm, range: 0.2-1.2 mm) than in the other two groups (median 1.2 mm, range: 0.4-5.0 mm). The five-year RFS rates in the high, moderate, and low groups were 80.0%, 96.0%, and 75.8%, respectively. Multivariate analysis revealed that pathological stage, lymphatic/vascular invasion, and SLX intensity were independent predictors of recurrence.
SLX staining cannot predict the presence of STAS; however, it can predict the distance between STAS and the main tumor in stage I lung adenocarcinoma.
肿瘤通过肺泡空间扩散(STAS)是一种最近描述的侵袭模式,与肺腺癌的预后和复发有关。本研究旨在确定 SLX 的免疫组织化学强度是否可以预测 STAS 的存在和距离,SLX 是一种已知的细胞粘附蛋白。
总共从 1998 年至 2012 年确定了 245 名接受肺叶切除术和根治性纵隔淋巴结清扫术的病理 I 期肺腺癌患者。根据 STAS 和主肿瘤中 SLX 的免疫组织化学强度对患者进行分层,比较无复发生存率(RFS)。根据 SLX 染色强度将患者分为三组:高(n = 108)、中(n = 48)和低(n = 89)。
71 例患者(29.0%)观察到 STAS。有 STAS 的患者五年 RFS(67.1%)明显低于无 STAS 的患者(84.8%)。尽管未观察到 STAS 的存在与 SLX 强度之间存在关系,但在中度组(中位距离 0.9 毫米,范围:0.2-1.2 毫米),STAS 细胞与主肿瘤之间的距离明显短于其他两组(中位距离 1.2 毫米,范围:0.4-5.0 毫米)。高、中、低三组五年 RFS 率分别为 80.0%、96.0%和 75.8%。多变量分析显示,病理分期、淋巴/血管侵犯和 SLX 强度是复发的独立预测因素。
SLX 染色不能预测 STAS 的存在;然而,它可以预测 I 期肺腺癌中 STAS 与主肿瘤之间的距离。